


WHAT IS CLAIMED IS:







1. A compound of Formula (1) or a pharmaceutically acceptable salt thereof:




- 5 wherein:
- X_1 is CR_1 or N;
- X_2 is CR_2 or N;
- X_3 is CR_3 or N;
- X_4 is CR_4 or N;
- 10 each of R_1 , R_2 , R_3 , and R_4 is independently selected from hydrogen, halogen, C_1 - C_3 alkoxy, and C_1 - C_3 haloalkyl, each of which is substituted with 0, 1, 2, or 3 R_S ;
- each R_5 is independently selected from halogen, hydroxyl, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_1 - C_3 haloalkyl, $-N(R_9)_2$, and $-CN$, each of which is substituted with 0, 1, 2, or 3 R_S ;
- each R_6 is independently selected from hydrogen, halogen, C_1 - C_3 alkyl, and C_1 - C_3 haloalkyl, each
- 15 of which is substituted with 0, 1, 2, or 3 R_S , or two R_6 groups are taken together to form an oxo;
- each R_7 is independently selected from halogen, hydroxyl, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_1 - C_3 haloalkyl, $-N(R_9)_2$, and $-CN$, each of which is substituted with 0, 1, 2, or 3 R_S ;
- each R_8 is independently selected from hydrogen, hydroxyl, C_1 - C_3 alkyl, and C_1 - C_3 haloalkyl, each
- 20 of which is substituted with 0, 1, 2, or 3 R_S , or two R_8 groups are taken together to form an oxo;
- each R_9 is independently selected from hydrogen, C_1 - C_3 alkyl, $-C(=O)-(C_1-C_3alkyl)$, $-C(=O)-O-(C_1-C_3alkyl)$, and $-C(=O)-NH-(C_1-C_3alkyl)$, each of which is substituted with 0, 1, 2, or 3 R_S , or two R_9 groups are taken together to form a 3- to 6-membered heterocycle or heteroaryl;
- each R_S is independently selected from halogen, hydroxyl, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, C_1 - C_3 haloalkyl, $-N(R_9)_2$, and $-CN$;
- 25 L is a linker of 1 to 16 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by $C(O)$, O , $N(R_9)$, S , C_2 -alkenyl, C_2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9 , C_2 -alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_S ;
- m is 0, 1, or 2;
- 30 n is 0, 1, 2, or 3; and
- o is 0, 1, 2, or 3,
- wherein each hydrogen atom is independently and optionally replaced by a deuterium atom.
2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein X_1 is N.

3. The compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein X₂ is N.
4. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein X₁ and X₂ are each N.
- 5 5. The compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein X₂ is CR₂, X₃ is CR₃, and X₄ is CR₄.
6. The compound or pharmaceutically acceptable salt thereof according to claim 5, wherein R₂, R₃, and R₄ are each independently selected from H and F.
7. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein X₁ is
- 10 CR₁, X₂ is CR₂, X₃ is CR₃, and X₄ is CR₄.
8. The compound or pharmaceutically acceptable salt thereof according to claim 7, wherein R₁, R₂, R₃, and R₄ are each independently selected from H and F.
9. The compound or pharmaceutically acceptable salt thereof according to claim 7 or 8, wherein R₁ is F.
- 15 10. The compound or pharmaceutically acceptable salt thereof according to claim 7 or 8, wherein R₂ is F.
11. The compound or pharmaceutically acceptable salt thereof according to claim 7 or 8, wherein R₃ is F.
12. The compound or pharmaceutically acceptable salt thereof according to claim 7 or 8, wherein R₄
- 20 is F.
13. The compound or pharmaceutically acceptable salt thereof according to claim 7 or 8, wherein R₁ and R₃ are each F.
14. The compound or pharmaceutically acceptable salt thereof according to claim 7 or 8, wherein R₃ and R₄ are each F.
- 25 15. The compound or pharmaceutically acceptable salt thereof according to claim 9, wherein R₂, R₃, and R₄ are each H.
16. The compound or pharmaceutically acceptable salt thereof according to claim 10, wherein R₁, R₃, and R₄ are each H.
17. The compound or pharmaceutically acceptable salt thereof according to claim 11, wherein R₁, R₂,
- 30 and R₄ are each H.
18. The compound or pharmaceutically acceptable salt thereof according to claim 12, wherein R₁, R₂, and R₃ are each H.
19. The compound or pharmaceutically acceptable salt thereof according to claim 13, wherein R₂ and R₄ are each H.
- 35 20. The compound or pharmaceutically acceptable salt thereof according to claim 14, wherein R₁ and R₂ are each H.


21. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the

 group is selected from , , , , ,




22. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 21, wherein each R_5 is independently selected from halogen, C_1 - C_3 alkoxy, and C_1 - C_3 haloalkyl.
23. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 22, wherein each R_5 is independently selected from -Cl, -OCH₃, and -CF₃.
24. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 23, wherein m is 0 or 1.
- 10 25. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 24, wherein m is 0.
26. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 25, wherein m is 1.
27. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 26, 15 wherein o is 0.
28. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 26, wherein o is 1.
29. The compound or pharmaceutically acceptable salt according to any one of claims 1 to 23, wherein m and o are each 0.
- 20 30. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 29, wherein each R_6 is independently selected from H and C_1 - C_3 alkyl.
31. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 30, wherein each R_6 is independently selected from H and -CH₃.
32. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 25 31, wherein the two R_6 groups attached to the same carbon are identical.
33. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 31, wherein each R_6 is identical.
34. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 31, wherein each R_6 is different.

35. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to



36. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to



37. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 36, wherein each R₇ is independently selected from halogen, hydroxyl, C₁-C₃alkyl, and C₁-C₃haloalkyl.

10 38. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 37, wherein each R₇ is independently selected from halogen, hydroxyl, -CH₃, and -CF₃.

39. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 38, wherein each R₇ is independently selected from F, hydroxyl, -CH₃, and -CF₃.

40. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 15 39, wherein each R₇ is independently F.

41. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 37, wherein n is 0.

42. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 37, wherein n is 1.



20 43. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 42, wherein each R₈ is hydrogen or two R₈ groups are taken together to form an oxo.

44. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 42, wherein each R₈ is hydrogen.

45. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 25 42, wherein two R₈ groups are taken together to form an oxo.

46. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 45, wherein each R₉ is independently selected from hydrogen, C₁-C₃alkyl, and -C(=O)-C₁-C₃alkyl.

47. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 46, wherein each R_9 is independently selected from hydrogen and C_1 - C_3 alkyl.
48. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 47, wherein each R_9 is independently selected from hydrogen, $-CH_3$, $-CH_2CH_3$, and $-CH(CH_3)_2$.
- 5 49. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to



- 10 50. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 49, wherein L is a linker of 1 to 12 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by $C(=O)$, O, $N(R_9)$, S, C_2 -alkenyl, C_2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9 , C_2 -alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_s .
- 15 51. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 50, wherein L is a linker of 1 to 10 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by $C(=O)$, O, $N(R_9)$, S, C_2 -alkenyl, C_2 -alkynyl, cycloalkyl, aryl, heterocycle, or

heteroaryl, wherein the R_9 , C_2 -alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_s .

52. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 51, wherein L is a linker of 1 to 8 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(=O), O, N(R_9), S, C_2 -alkenyl, C_2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9 , C_2 -alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_s .

53. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 52, wherein L is a linker of 1 to 6 carbon atoms in length, wherein one or more carbon atoms are optionally replaced by C(=O), O, N(R_9), S, C_2 -alkenyl, C_2 -alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9 , C_2 -alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_s .

54. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 53, wherein one or more carbon atoms of linker L are optionally replaced by C(=O), O, N(R_9), S, cycloalkyl, aryl, heterocycle, or heteroaryl, wherein the R_9 , C_2 -alkenyl, cycloalkyl, aryl, heterocycle, and heteroaryl are each independently substituted with 0, 1, 2, or 3 R_s .



55. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 54, wherein one or more carbon atoms of linker L are optionally replaced by O, N(R_9), cycloalkyl, or heterocycle, wherein the R_9 , cycloalkyl, and heterocycle are each independently substituted with 0, 1, 2, or 3 R_s .

56. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 55, wherein at least one carbon atom of linker L is replaced by a heterocycle, which is substituted with 0, 1, 2, or 3 R_s .


57. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 55, wherein at least two carbon atoms of linker L are replaced by a heterocycle, each of which is substituted with 0, 1, 2, or 3 R_s .


58. The compound or pharmaceutically acceptable salt thereof according to claim 56 or 57, wherein the heterocycle is selected from piperidine and piperazine, each of which is substituted with 0, 1, 2, or 3 R_s .

59. The compound or pharmaceutically acceptable salt thereof according to claim 56 or 57, wherein

the heterocycle is selected from  and .

60. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to

49, wherein L is selected from: 



61. The compound according to claim 1, wherein the compound is chosen from:

1	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-((5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)oxy)pentyl)oxy)benzamide;
2	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)oxy)propoxy)propoxy)benzamide;
3	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)ethoxy)benzamide
4	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)propoxy)benzamide
5	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)butoxy)benzamide
6	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-((5-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)pentyl)oxy)benzamide
7	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)nicotinamide
8	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)oxy)cyclobutyl)(methyl)amino)butoxy)benzamide
9	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)oxy)cyclobutyl)(methyl)amino)methyl)piperidin-1-yl)nicotinamide
10	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)oxy)cyclobutyl)(ethyl)amino)methyl)piperidin-1-yl)nicotinamide

11	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)nicotinamide
12	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(((1s,3s)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)nicotinamide
13	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
14	N-((1S,3S)-3-((8-cyanoquinolin-5-yl)oxy)-2,2-dimethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
15	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)cyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
16	N-((1s,3s)-3-((8-cyanoquinolin-5-yl)oxy)cyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
17	N-((1S,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2-dimethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
18	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide
19	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide
20	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-5-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrazine-2-carboxamide
21	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide
22	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide
23	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)ethyl)piperazin-1-yl)-3-fluorobenzamide
24	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)-3-fluorobenzamide
25	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)nicotinamide
26	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyrimidine-5-carboxamide
27	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)pyridazine-3-carboxamide
28	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)-5-fluoronicotinamide
29	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide

30	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide
31	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide
32	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide
33	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
34	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide
35	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide
36	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
37	N-((1r,3S)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(((2S)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
38	N-((1r,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(((2R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)nicotinamide
39	N-((1r,3S)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2S)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)benzamide
40	N-((1r,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)benzamide
41	N-((1r,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2R)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)-2-methylpiperazin-1-yl)methyl)piperidin-1-yl)benzamide
42	N-((1r,3R)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2R)-2-((dimethylamino)methyl)-4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide
43	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)ethyl)piperidin-1-yl)benzamide
44	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-(((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)oxy)cyclobutyl)(isopropyl)amino)methyl)piperidin-1-yl)pyridazine-3-carboxamide
45	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((2-(dimethylamino)ethyl)((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)oxy)cyclobutyl)amino)methyl)piperidin-1-yl)-3-fluorobenzamide
46	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-5-fluoronicotinamide
47	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide

48	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide
49	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)benzamide
50	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-2-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyrimidine-5-carboxamide
51	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide
52	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-5-fluoronicotinamide
53	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-((4-(2-((S)-2,6-dioxopiperidin-3-yl)-6-fluoro-1-oxoisindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)-3-fluorobenzamide
54	N-((1r,3r)-3-((8-cyanoquinolin-5-yl)oxy)-2,2,4,4-tetramethylcyclobutyl)-4-(4-(((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)oxy)cyclobutyl)(ethyl)amino)methyl)piperidin-1-yl)benzamide

or a pharmaceutically acceptable salt thereof, wherein each hydrogen is independently and optionally replaced by a deuterium.

62. A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 61 and a pharmaceutically acceptable carrier.

63. The pharmaceutical composition according to claim 62, wherein the compound or pharmaceutically acceptable salt thereof is present in a therapeutically effective amount.

64. A method of treating cancer in a subject in need thereof, comprising administering to said subject a compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 61 or a pharmaceutical composition according to claim 62 or 63.

65. The method according to claim 64, wherein the cancer is selected from prostate cancer, head and neck cancer, skin cancer, sarcoma, renal cell carcinoma, adrenocortical carcinoma, bladder cancer, lung cancer, gastric carcinoma, esophageal carcinoma, pancreatic adenocarcinoma, colorectal cancer, connective tissue cancer, glioblastoma multiforme, cervical cancer, uterine cancer, ovarian cancer, and breast cancer.

66. The method according to claim 64 or 65, wherein the cancer is prostate cancer.

67. The method according to any one of claims 64 to 66, wherein the cancer is androgen receptor positive.

68. The method according to any one of claims 64 to 67, wherein the subject has been previously treated with an anti-cancer agent.

69. The method according to claim 68, wherein the anti-cancer agent is enzalutamide, apalutamide, bicalutamide, darolutamide, flutamide, abiraterone, or a combination of any of the foregoing.

70. The method according to claim 69, wherein the anti-cancer agent is enzalutamide.

- 25 positive.

